AUG 14, 2020 12:25 PM PDT

Controlling Tumor Blood Flow to Increase Therapy Effectiveness

WRITTEN BY: Jasper Cantrell

Nowadays, most cancer drugs target a protein or inhibit a critical cellular process. Modern therapies have varying levels of success, but often we overlook something. How these drugs get to the tumor.

As of now, the most common way to get a drug to a tumor is to target a protein that the tumors are overexpressing, or relying on a tumor’s general high resource demand. The drug would then be injected into the patient, and circulate through the bloodstream until it reaches the tumor. In the case of melanoma, there may be a better way of targeting therapies to tumors.

In-transit melanoma is a rare and dangerous type of skin cancer. There are chemo- and immunotherapies that could treat it, but a team from the Mayo Clinic in Florida wanted to try another route. They intended to develop a modern interpretation of an old school treatment for in-transit melanoma, called isolated limb infusion. It involves the direct injection of high dose chemotherapy directly into the affected area via a catheter. There tended to be high response rates to this older method, but results were not consistent.

The team redeveloped the method by effectively controlling the flow of blood in a tumor. They note that tumors often have non-functioning or closed blood vessels, which, if opened, may allow a drug to have increased exposure to the tumor itself. They developed a protocol of injecting saline bolus (a salt solution) followed by two phenylephrine (a vasoconstrictor) injections. The saline bolus would initiate a significant increase in blood flow through the tumor vasculature, while the phenylephrine would slow the blood flow afterward. They termed this dynamic control.

The team tested their method in a melanoma mouse model. The mice were treated with a negative control, dynamic control alone, the drug melphalan alone, or a combination of dynamic control and melphalan. The combination therapy had the best results, significantly outcompeting melphalan alone. Dynamic control was surprisingly better than the negative control used, although still nowhere near as effective as melphalan or combination therapy.

Other studies have done similar experiments, using vasoconstrictors (phenylephrine in this study’s case) to increase the effectiveness of a chemo- or immunotherapy. This study combined this with a targeted approach and was the first to measure the actual changes in blood flow during the procedure. While the method worked well in combination with chemotherapy, there was an interesting increase in survival for mice with dynamic control alone. The team postulates this could be due to increased immune activity, as dynamic control technically increases a tumor’s overall blood exposure.

The study concludes, “…we provide the first evidence that dynamic control of tumor vessels was feasible and directly observable via IVM using our protocol of volume expansion (saline bolus) plus phenylephrine.” They say this increased the effectiveness of drug delivery to the tumor, thereby improving the therapy overall. The best thing about this method is that it could work for many tumor presenting cancers, not just for in-transit melanoma.

Sources: Nature Scientific Reports, Moffit Cancer Center

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
AUG 06, 2020
Immunology
Resetting the Body's Danger Sensor
AUG 06, 2020
Resetting the Body's Danger Sensor
The human body has a sophisticated danger-sensing mechanism that alerts the immune system when something is not right. T ...
AUG 12, 2020
Cancer
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
AUG 12, 2020
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer
Since the 1940s, chemotherapy has been a primary treatment option for cancer. The late 20th century brought a new type o ...
SEP 18, 2020
Cancer
Itraconazole: the key is in the dosage
SEP 18, 2020
Itraconazole: the key is in the dosage
Precision medicine specific to a patient’s genetics or immune system is spearheading new paths of cancer treatment ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
SEP 30, 2020
Cancer
Chemokines Could be the Key in Controlling Glioma Stem Cells
SEP 30, 2020
Chemokines Could be the Key in Controlling Glioma Stem Cells
The transformation of a healthy cell into a cancerous one often comes with a slew of cellular signaling changes.  T ...
OCT 01, 2020
Cancer
Understanding in vivo Metabolomics: C13 Isotope Studies
OCT 01, 2020
Understanding in vivo Metabolomics: C13 Isotope Studies
One key to understanding cancer metabolomics lies in the ability to accurately replicate the natural environment of the ...
Loading Comments...